In the preceding three months, 19 analysts have released ratings for Axsome Therapeutics AXSM, presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 9 | 9 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 2 | 4 | 0 | 0 | 0 |
| 2M Ago | 6 | 2 | 0 | 0 | 0 |
| 3M Ago | 1 | 2 | 1 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $128.05, a high estimate of $180.00, and a low estimate of $95.00. This current average has increased by 0.5% from the previous average price target of $127.41.
Investigating Analyst Ratings: An Elaborate Study
The standing of Axsome Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Leonid Timashev | RBC Capital | Raises | Outperform | $131.00 | $130.00 |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $107.00 | $107.00 |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $107.00 | $107.00 |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $107.00 | $107.00 |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $107.00 | $107.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Maintains | Buy | $180.00 | $180.00 |
| Ami Fadia | Needham | Maintains | Buy | $130.00 | $130.00 |
| Cerena Chen | Wells Fargo | Announces | Overweight | $140.00 | - |
| Raghuram Selvaraju | HC Wainwright & Co. | Maintains | Buy | $180.00 | $180.00 |
| Ashwani Verma | UBS | Lowers | Buy | $105.00 | $107.00 |
| Leonid Timashev | RBC Capital | Lowers | Outperform | $130.00 | $131.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Lowers | Buy | $180.00 | $190.00 |
| Jason Gerberry | B of A Securities | Raises | Buy | $106.00 | $95.00 |
| Ami Fadia | Needham | Maintains | Buy | $130.00 | $130.00 |
| Ami Fadia | Needham | Maintains | Buy | $130.00 | $130.00 |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $107.00 | $107.00 |
| Leonid Timashev | RBC Capital | Maintains | Outperform | $131.00 | $131.00 |
| Ami Fadia | Needham | Announces | Buy | $130.00 | - |
| Jason Gerberry | B of A Securities | Lowers | Neutral | $95.00 | $97.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Axsome Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Axsome Therapeutics compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Axsome Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Axsome Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Axsome Therapeutics analyst ratings.
Delving into Axsome Therapeutics's Background
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Axsome Therapeutics: A Financial Overview
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Axsome Therapeutics's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 86.65%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Axsome Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -91.03%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Axsome Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -64.28%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Axsome Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -14.51%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Axsome Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.86.
The Basics of Analyst Ratings
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
